Calliditas Therapeutics Q2 2024 GAAP EPS $(0.17) Misses $(0.13) Estimate, Sales $52.351M Beat $42.952M Estimate
Portfolio Pulse from Benzinga Newsdesk
Calliditas Therapeutics (NASDAQ:CALT) reported Q2 2024 GAAP EPS of $(0.17), missing the $(0.13) estimate, but achieved sales of $52.351M, beating the $42.952M estimate. EPS improved by 49.23% YoY, and sales increased by 104.45% YoY.
August 13, 2024 | 5:40 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Calliditas Therapeutics reported Q2 2024 GAAP EPS of $(0.17), missing the $(0.13) estimate, but achieved sales of $52.351M, beating the $42.952M estimate. EPS improved by 49.23% YoY, and sales increased by 104.45% YoY.
Despite missing EPS estimates, Calliditas Therapeutics showed significant YoY improvement in both EPS and sales. The strong sales performance, which beat estimates by 21.88%, is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100